10x Genomics GAAP EPS of -$0.15 beats by $0.11, revenue of $150.7M beats by $2.85M (NASDAQ:TXG)
10x Genomics reported Q3 GAAP EPS of -$0.15, beating estimates by $0.11. Revenue was $150.7M, up 1.1% year-over-year and exceeding expectations by $2.85M. The company had $575.7M in cash and equivalents as of September 30, 2026, and announced a raise.
How this was made
The 30-second read
Why it matters
The earnings beat is likely to generate short-term buying interest, especially given the strong cash position.
Market read
First-report earnings beat for a mid-cap biotech, offering a fresh catalyst for traders.
What to watch
Cash balance of $575.7M provides runway for R&D or acquisitions, which could affect future performance.
Background
10x Genomics released its Q3 2026 earnings, reporting a GAAP EPS beat and a slight revenue beat.
Ticker impact
Q3 GAAP EPS of -$0.15 beats expectations by $0.11 and revenue of $150.7M beats by $2.85M, marking the first public disclosure of the earnings results.
likely upward pressure as the market prices in the earnings beat
Both EPS and revenue exceeded consensus, indicating improved operating trends and cash position.
Market effects
Positive earnings may lift the genomics and biotech sector as investors reassess growth prospects.
U.S. biotech stocks could see modest gains following the beat.
Limited to investors tracking U.S. biotech earnings.
Counterpoint
The beat may be modest relative to peers; valuation could already reflect expectations, limiting upside.
Key entities
- company10x Genomics, Inc.
U.S.-listed genomics technology firm (NASDAQ:TXG).
